DARA Biosciences, a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care products, announced today that Haywood D. Cochrane Jr. has been appointed chairman of the DARA board of directors and Paul Richardson has been appointed as a new board member.
Mr. Cochrane has been serving as a member of DARA’s board since February 2008. He has accumulated more than 30 years of executive and senior management experience in the healthcare industry. This experience includes senior vice president and chief operating officer positions at Roche Biomedical Laboratories, as well as serving as president and chief financial officer of Allied Clinical Laboratories and executive vice president and chief financial officer of Laboratory Corporation of America. Mr. Cochrane attended the University of North Carolina at Chapel Hill where he earned an A.B. degree in political science and was a Morehead Scholar.
“Haywood brings our board extensive executive and senior management experience in the healthcare industry and extraordinary abilities as a communicator and board facilitator. His relevant business expertise and leadership experience acquired through serving as vice chairman and chairman of the boards of directors of other healthcare-related companies make Haywood an outstanding choice to serve as the chairman of the board for DARA,” said David J. Drutz, M.D., DARA’s chief executive officer.
Mr. Richardson has an impressive background featuring over 30 years of senior executive experience in the bio-pharmaceutical industry. Throughout his career, Mr. Richardson has developed extensive, far-reaching experience in global product commercialization and development. Mr. Richardson possesses extensive strategic, managerial, and commercial skills that DARA can effectively leverage to grow in the future. Most recently, Mr. Richardson served as the President for Pfizer’s North American Specialty Business. Overall, Mr. Richardson’s expansive skill set strengthens DARA’s board by providing additional expertise in global commercial and development strategy.
Dr. Drutz concluded, “We are very grateful to have a board of directors with the experience, knowledge, and expertise necessary to support DARA in its ongoing efforts to become a preeminent oncology and oncology supportive care company.”
For further information, visit www.darabio.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
